- Home
- THQ vs MNMD Comparison
THQ vs MNMD Comparison
Compare THQ & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THQ
- MNMD
- Stock Information
- Founded
- THQ 2014
- MNMD 2019
- Country
- THQ United States
- MNMD United States
- Employees
- THQ N/A
- MNMD N/A
- Industry
- THQ Finance Companies
- MNMD Pharmaceuticals and Biotechnology
- Sector
- THQ Finance
- MNMD Health Care
- Exchange
- THQ Nasdaq
- MNMD Nasdaq
- Market Cap
- THQ 714.6M
- MNMD 811.9M
- IPO Year
- THQ N/A
- MNMD N/A
- Fundamental
- Price
- THQ $18.20
- MNMD $12.47
- Analyst Decision
- THQ
- MNMD Strong Buy
- Analyst Count
- THQ 0
- MNMD 6
- Target Price
- THQ N/A
- MNMD $26.50
- AVG Volume (30 Days)
- THQ 158.9K
- MNMD 1.8M
- Earning Date
- THQ 01-01-0001
- MNMD 11-06-2025
- Dividend Yield
- THQ 7.53%
- MNMD N/A
- EPS Growth
- THQ N/A
- MNMD N/A
- EPS
- THQ N/A
- MNMD N/A
- Revenue
- THQ N/A
- MNMD N/A
- Revenue This Year
- THQ N/A
- MNMD N/A
- Revenue Next Year
- THQ N/A
- MNMD N/A
- P/E Ratio
- THQ N/A
- MNMD N/A
- Revenue Growth
- THQ N/A
- MNMD N/A
- 52 Week Low
- THQ $15.29
- MNMD $4.70
- 52 Week High
- THQ $20.38
- MNMD $12.94
- Technical
- Relative Strength Index (RSI)
- THQ 69.60
- MNMD 65.53
- Support Level
- THQ $17.98
- MNMD $11.81
- Resistance Level
- THQ $18.30
- MNMD $12.94
- Average True Range (ATR)
- THQ 0.28
- MNMD 0.86
- MACD
- THQ 0.10
- MNMD 0.17
- Stochastic Oscillator
- THQ 90.45
- MNMD 87.28
About THQ abrdn Healthcare Opportunities Fund Shares of Beneficial Interest
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. The fund's investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).